Fractyl Health (GUTS) EPS (Weighted Average and Diluted) (2023 - 2026)
Fractyl Health (GUTS) reported EPS (Weighted Average and Diluted) of $0.06 for Q1 2026, up 112.24% year-on-year from $0.03 in Q1 2025, and up 185.71% quarter-over-quarter from -$0.07 in Q4 2025.
Fractyl Health (GUTS) has 4 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.06 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 112.24% year-over-year to $0.06; the trailing twelve-month figure through Mar 2026 stood at -$1.29 (up 30.65% YoY), and the FY2025 full-year result was -$1.86, down 14.81% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.06, up from -$0.07 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.06 in Q1 2026 and bottomed at -$16.62 in Q2 2023.
- A 4-year average of -$3.74 and a median of -$0.53 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) sank 188.24% in 2025 and soared 112.24% in 2026, its largest moves.
- Tracing GUTS's EPS (Weighted Average and Diluted) over 4 years: stood at -$11.18 in 2023, then surged by 95.26% to -$0.53 in 2024, then soared by 86.79% to -$0.07 in 2025, then jumped by 185.71% to $0.06 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $0.06, -$0.07, and -$0.71 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 4.02 |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 6.75 |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 1.51 |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | 0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.06 |
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | -0.71 |
| Jun 30, 2025 | -0.57 |
| Mar 31, 2025 | -0.49 |
| Dec 31, 2024 | -0.53 |
| Sep 30, 2024 | -0.48 |
| Jun 30, 2024 | -0.36 |
| Mar 31, 2024 | -0.17 |
| Dec 31, 2023 | -11.18 |
| Sep 30, 2023 | -9.61 |
| Jun 30, 2023 | -16.62 |
| Mar 31, 2023 | -7.87 |